Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Plus Therapeutics (PSTV) Share-based Compensation (2016 - 2025)

Plus Therapeutics (PSTV) has disclosed Share-based Compensation for 16 consecutive years, with $527000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Share-based Compensation rose 321.6% to $527000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $955000.0, a 69.63% increase, with the full-year FY2024 number at $550000.0, down 3.34% from a year prior.
  • Share-based Compensation was $527000.0 for Q3 2025 at Plus Therapeutics, up from $152000.0 in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $527000.0 in Q3 2025 to a low of $107000.0 in Q1 2021.
  • A 5-year average of $166187.5 and a median of $143500.0 in 2023 define the central range for Share-based Compensation.
  • Peak YoY movement for Share-based Compensation: surged 791.67% in 2021, then dropped 22.22% in 2023.
  • Plus Therapeutics' Share-based Compensation stood at $107000.0 in 2021, then increased by 21.5% to $130000.0 in 2022, then increased by 8.46% to $141000.0 in 2023, then decreased by 9.22% to $128000.0 in 2024, then surged by 311.72% to $527000.0 in 2025.
  • Per Business Quant, the three most recent readings for PSTV's Share-based Compensation are $527000.0 (Q3 2025), $152000.0 (Q2 2025), and $148000.0 (Q1 2025).